The basis for monitoring strategies in clinical guidelines: A case study of prostate-specific antigen for monitoring in prostate cancer

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 2, 2012, Pages 169-177

  Dinnes, Jacqueline ^a   Hewison, Jenny ^b   Altman, Douglas G ^c   Deeks, Jonathan J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BIOCHEMICAL FAILURE; CANCER RADIOTHERAPY; CANCER RECURRENCE; PATIENT MONITORING; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY; TREATMENT FAILURE;

EID: 84856799666     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.110600     Document Type: Article

References (43)

1. Glasziou PP, Aronson JK. An introduction to monitoring therapeutic interventions in clinical practice. In: Glasziou PP, Irwig L, Aronson JK, editors. Evidence-based medical monitoring: from principles to practice. Oxford (UK): Blackwell Publishing; 2008. p. 3-14.
2. Mant D. A framework for developing and evaluating a monitoring strategy. In: Glasziou PP, Irwig L, Aronson JK, editors. Evidence-based medical monitoring: from principles to practice. Oxford (UK): Blackwell Publishing; 2008. p. 15-30.
3. Irwig L, Glasziou PP. Choosing the best monitoring tests. In: Glasziou PP, Irwig L, Aronson JK, editors. Evidence-based medical monitoring: from principles to practice. Oxford (UK): Blackwell Publishing; 2008. p. 63-74.
4. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-78. (Pubitemid 351430866)
5. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540-5. (Pubitemid 46054056)
6. The AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12:18-23.
7. The Royal College of Radiologists' Clinical Oncology Information Network, British Association of Urological Surgeons. Guidelines on the management of prostate cancer. Clin Oncol (R Coll Radiol) 1999;11:S53-88.
8. Australian Cancer Network Working Party on Management of Localised Prostate Cancer. Clinical practice guidelines: evidence-based information and recommendations for the management of localised prostate cancer. Canberra (Australia): National Health and Medical Research Council; 2002.
9. American Urological Association. Guideline for the management of clinically localized prostate cancer: 2007 update. Linthicum (MD): American Urological Association Education and Research; 2007.
10. Dutch Urological Association. Prostate cancer. Nation-wide guideline version 1.0. Utrecht (Netherlands): Dutch Institute for Healthcare Improvement CBO; 2007.
11. National Cancer Institute. Prostate Cancer Treatment (PDQ®). Bethesda (MD): The Institute; 2008. Available: http://cancer.gov/cancertopics/pdq/ treatment/prostate/HealthProfessional (accessed 2010 July 15).
12. National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. Cardiff (UK): National Collaborating Centre for Cancer; 2008.
13. American Urological Association. Prostate-specific antigen best practice statement: 2009 update. Linthicum (MD): American Urological Association Education and Research; 2009.
14. Heidenreich A, Bolla M, Joniau S, et al. EAU guidelines on prostate cancer. Arnhem (Netherlands): European Association of Urology; 2009.
15. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. The Network; 2009.
16. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
17. Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
18. Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006;65:1487-93. (Pubitemid 44425220)
19. Horwitz EM, Thames HD, Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 2005;173:797-802. (Pubitemid 40239344)
20. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24:3973-8. (Pubitemid 46630746)
21. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. (Pubitemid 29211767)
22. Sölétormos G, Semjonow A, Sibley PE, et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005;51:1342-51. (Pubitemid 41060864)
23. Whiting P, Rutjes AW, Reitsma JB, et al. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004;140:189-202. (Pubitemid 38155650)
24. Vicini FA, Vargas C, Abner A, et al. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 2005;173:1456-62. (Pubitemid 40524749)
25. Parker E, Glasziou P. Use of evidence in hypertension guidelines: should we measure in both arms? Br J Gen Pract 2009;59:e87-92.
26. Moschetti I, Brandt D, Perera R, et al. Accuracy of reporting monitoring regimens of risk factors for cardiovascular disease in clinical guidelines: systematic review. BMJ 2011;342:d1289.
27. Cruse H, Winiarek M, Marshburn J, et al. Quality and methods of developing practice guidelines. BMC Health Serv Res 2002;2:1.
28. Savoie I, Kazanjian A, Bassett K. Do clinical practice guidelines reflect research evidence? J Health Serv Res Policy 2000;5:76-82. (Pubitemid 30195326)
29. Campbell F, Dickinson HO, Cook JV, et al. Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall. BMC Health Serv Res 2006;6:47.
30. McAlister FA, van Diepen S, Padwal RS et al. How evidence-based are the recommendations in evidence-based guidelines? PLoS Med 2007;4:e250.
31. Burgers JS, Vailey JV, Klazinga NS, et al. Comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. Diabetes Care 2002;25:1933-9. (Pubitemid 41071047)
32. Glasziou PP, Irwig L, Aronson JK. Evidence-based medical monitoring: from principles to practice. 1st ed. Oxford (UK): Blackwell Publishing; 2008.
33. Bossuyt PM. Evaluating the effectiveness and costs of monitoring. In: Glasziou PP, Irwig L, Aronson JK, editors. Evidencebased medical monitoring: from principles to practice. Oxford (UK): Blackwell Publishing; 2008. p. 158-65.
34. Bellera CA, Hanley JA, Joseph L, et al. A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancer. Int J Radiat Oncol Biol Phys 2009;75:1357-63.
35. Stevens RJ, Oke J, Perera R. Statistical models for the control phase of clinical monitoring. Stat Methods Med Res 2010;19:394-414.
36. Glasziou PP, Irwig L, Heritier S, et al. Monitoring cholesterol levels: Measurement error or true change? Ann Intern Med 2008;148:656-61. (Pubitemid 351669110)
37. Keenan K, Hayen A, Neal BC, et al. Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. BMJ 2009;338:b1492.
38. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761-73. (Pubitemid 38857461)
39. Buclin T, Telenti A, Perera R, et al. Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy. PLoS ONE 2011;6:e18578.
40. National Institute for Health and Clinical Excellence. The guidelines manual. London (UK): NICE; 2009.
41. Brouwers M, Kho ME, Browman GP et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010;182:E839-42.
42. Hillier S, Grimmer-Somers K, Merlin T, et al. FORM: an Australian method for formulating and grading recommendations in evidence-based clinical guidelines. BMC Med Res Methodol 2011;11:23.
43. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical practice guidelines we can trust. Washington (DC): The National Academies Press; 2011.